Publication Name	World Journal of Gastroenterology
Manuscript ID	10822
Country	China

Received	2014-04-21 21:31
Peer-Review Started	2014-04-22 20:01
To Make the First Decision	2014-05-29 19:23
Return for Revision	2014-06-04 20:40
Revised	2014-07-05 22:05
Second Decision	2014-08-28 10:00
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-08-28 10:26
Articles in Press	2014-08-28 10:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-12-11 14:22
Publish the Manuscript Online	2014-12-20 19:42

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No.16968 trials
Manuscript Source	Unsolicited Manuscript
All Author List	Feng Wen, Ke Yao, Ze-Dong Du, Xiao-Feng He, Peng-Fei Zhang, Rui-Lei Tang and Qiu Li
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 81071862
Corresponding Author	Qiu Li, MD, PhD, Professor, Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Guoxuexiang 37, Wuhou District, Chengdu 610041, Sichuan Province, China. fbqiu9@163.com
Key Words	Cost-effectiveness; Adjuvant chemotherapy; Colon cancer; FOLFOX; XELOX
Core Tip	Notably, patients with stage III colon cancer are recommended to receive either XELOX or FOLFOX4 as adjuvant therapy. However, there has not been a cost-effectiveness analysis of these two regimens. This study compared XELOX and FOLFOX4 as adjuvant chemotherapy for patients with colon cancer based on the MOSAIC and No.16968 trails from a Chinese cost-effectiveness perspective. Our results demonstrated that XELOX was a more cost-effective treatment for adjuvant chemotherapy of colon cancer in China.
Publish Date	2014-12-20 19:42
Citation	Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. World J Gastroenterol 2014; 20(47): 17976-17984
URL	http://www.wjgnet.com/1007-9327/full/v20/i47/17976.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i47.17976

Full Article (PDF)	WJG-20-17976.pdf
Full Article (Word)	WJG-20-17976.doc
Manuscript File	10822-Review.doc
Answering Reviewers	10822-Answering reviewers.pdf
Copyright License Agreement	10822-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	10822-Language certificate.pdf
Peer-review Report	10822-Peer review.pdf
Scientific Misconduct Check	10822-CorssCheck.jpg
Scientific Editor Work List	10822-Scientific editor work list.pdf